Biography:Maureen Murphy (scientist)
Maureen E. Murphy is an American cancer researcher who works at The Wistar Institute in Philadelphia.[1][2][3] Her research focuses on the tumor suppressor genes p53 and the cancer survivor protein HSP70.[4] Previously, she was a faculty member at the Fox Chase Cancer Center from 1998 until moving to The Wistar Institute in 2011.[4]
Education and career
Murphy obtained her B.Sc. in biochemistry from Rutgers University in 1987 and her Ph.D. in Molecular Biology from the Perelman School of Medicine at the University of Pennsylvania in 1993. She performed her post-doctoral work in the lab of Arnold J. Levine at Princeton University. She was a faculty member at the Fox Chase Cancer Center from 1998 until moving to the Wistar Institute in 2011.[5]
Research
Murphy's research on p53 has focused on various genetic polymorphisms, or genetic variants, of p53 that exist in different populations, and which impair the ability of p53 to suppress cancer in those populations. In particular, her laboratory works on the P47S (Pro47Ser) and Y107H (Tyr107His) variants that exist in African-descent populations, and on the G334R (Gly334Arg) variant that exists in individuals of Ashkenazi descent. Using human cell lines and mouse models for these variants, her research indicates that these variants predispose to cancer risk. Murphy has also discovered anti-cancer agents that preferentially destroy tumors containing these variants in a personalized medicine approach. In addition, Murphy's research provides a possible explanation as to why certain types of cancer affect certain populations.[6][4][7]
Memberships and affiliations
Murphy serves on the international committee of the International p53 Workshop[8] and served as co-chair of the workshop in 2010.[9]
Select publications
- "A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers". Cancer Research 80 (17): 3732–3744. September 2020. doi:10.1158/0008-5472.CAN-20-1390. PMID 32675277.
- "African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin". Nature Communications 11 (1): 473. January 2020. doi:10.1038/s41467-019-14151-9. PMID 31980600.
- "Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53". Proceedings of the National Academy of Sciences of the United States of America 116 (17): 8390–8396. April 2019. doi:10.1073/pnas.1821277116. PMID 30962386.
- "Tailoring Chemotherapy for the African-Centric S47 Variant of TP53". Cancer Research 78 (19): 5694–5705. October 2018. doi:10.1158/0008-5472.CAN-18-1327. PMID 30115697.
- "A functionally significant SNP in TP53 and breast cancer risk in African-American women". npj Breast Cancer 3: 5. 2017. doi:10.1038/s41523-017-0007-9. PMID 28649645.
- Azzam GA, Wang X, Bell DA and Murphy ME. CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest. PLoS One, in press.
- Budina-Kolomets A, Hontz RD, Pimkina J, Murphy ME. A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. Autophagy 2013; Aug 7;9(10).
- Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013; 34(6):1181-8.
- Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL Jr, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 2013;11(3):219-29.
- Leu JI, Pimkina J, Pandey P, Murphy ME, George DL. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol Cancer Res. 2011; 9:936-47.
References
- ↑ "Maureen Murphy, Ph.D.". The Wistar Institute. http://www.wistar.org/our-science/scientists/maureen-murphy-phd. Retrieved 18 February 2014.
- ↑ "Maureen E. Murphy, Ph.D.". Perelman School of Medicine. http://www.med.upenn.edu/apps/faculty/index.php/g20001500/p6400708. Retrieved 18 February 2014.
- ↑ "Fox Chase professor leaving for Wistar". Philadelphia Business Journal. http://www.bizjournals.com/philadelphia/blog/john-george/2011/10/fox-chase-professor-leaving-for-wistar.html?page=all. Retrieved 18 February 2014.
- ↑ 4.0 4.1 4.2 "Common variant of p53 tumor suppressor gene linked to increased inflammatory responses". ScienceDaily. https://www.sciencedaily.com/releases/2011/04/110404151336.htm. Retrieved 18 February 2014.
- ↑ "Maureen E. Murphy, Ph.D." (in en). https://wistar.org/our-scientists/maureen-murphy.
- ↑ "p53 may affect susceptibility to cancer and other diseases". National Institute of Environmental Health Sciences. http://www.niehs.nih.gov/news/newsletter/2012/6/science-p53/. Retrieved 18 February 2014.
- ↑ "Genetic variant of p53 gene linked to breast cancer risk in premenopausal African American women: African American women who carry the genetic variant could have an increased risk of breast cancer before menopause -- ScienceDaily". 2023-03-15. https://www.sciencedaily.com/releases/2017/02/170227120312.htm.
- ↑ "Committees". 16th International p53 Workshop. http://www.p53sweden2014.com/committees/. Retrieved 18 February 2014.
- ↑ "The 15th International p53 Workshop will be held October 8-12, 2010 in Philadelphia at the University of Pennsylvania School of Medicine.". Abramson Cancer Center. http://penncancer.org/p53/. Retrieved 18 February 2014.
External links
 |  |
